Drug Detail

Information about Pazopanib + Trametinib

Generic Name
Pazopanib + Trametinib
IND
Brand Name (US)
Manufacturer
GlaxoSmithKline
Drug Type
Tyrosine Kinase Inhibitor
Delivery
Oral
Approval Status
Pazopanib is approved for RCC
Indications
RCC
Overall Strategy
KIT Protein Based + Oncogenic Signal Path Based
Strategy
Block KIT + Block related tumor signal paths
Drug Category
KIT/PDGFRA inhibitor + MEK inhibitor

The combination provides a KIT inhibitor + a MEK inhibitor (trametinib). The combination of a KIT inhibitor and a MEK inhibitor shows good activitiy against GIST cells in the lab.